These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9184695)

  • 1. Treatment of subcutaneous tumor with adoptively transferred T cells.
    Peng L; Shu S; Krauss JC
    Cell Immunol; 1997 May; 178(1):24-32. PubMed ID: 9184695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
    Korbelik M; Dougherty GJ
    Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
    Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
    J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.
    Plautz GE; Inoue M; Shu S
    Cell Immunol; 1996 Aug; 171(2):277-84. PubMed ID: 8806798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
    Frey AB; Cestari S
    Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic efficacy of murine anti-tumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro.
    Evans R; Kamdar SJ; Duffy TM; Krupke DM; Fuller JA; Dudley ME
    Anticancer Res; 1995; 15(2):441-7. PubMed ID: 7763019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory role of CD8+ T lymphocytes in bone marrow eosinophilopoiesis.
    Rådinger M; Sergejeva S; Johansson AK; Malmhäll C; Bossios A; Sjöstrand M; Lee JJ; Lötvall J
    Respir Res; 2006 Jun; 7(1):83. PubMed ID: 16740158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
    Ma J; Wang YL; Hu HM; Fox BA; Si LS
    Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.
    Stewart TJ; Smyth MJ; Fernando GJ; Frazer IH; Leggatt GR
    Cancer Res; 2003 Jun; 63(12):3058-60. PubMed ID: 12810627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
    J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
    Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
    Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.